CTRA three-lens brief
Evidence-based stock research on CTRA. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Price down 8.62% in the last session — a material single-day move. · Underperforming SPY by 20.8pp over 30 days.
- Price down 8.62% in the last session — a material single-day move.
- Underperforming SPY by 20.8pp over 30 days.
- Analyst mean target $37.65 — 16% above current (20 analysts).
- Debt-to-equity of 24.4 — balance-sheet-heavy.
CTRA closed at $32.56 (-8.62%) as of 2026-05-13. Market cap: $24.72B. P/E (trailing) 15.0. Positives: analyst mean target $37.65 — 16% above current (20 analysts).. Concerns: price down 8.62% in the last session — a material single-day move.; underperforming SPY by 20.8pp over 30 days.. Last quarter: Revenue $1.95B, net income $466.00M, free cash flow $1.25B.
Why three lenses on CTRA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CTRAacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CTRA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CTRA brief"></iframe>